9 results about "Mitosis" patented technology

The present invention relates to the field of therapy and drug delivery. More specifically, therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-protected organs that harbor substantial populations of postmittal neurons, such as organs derived from the neural tube, including the central nervous system and the eye. The disclosed methods and compositions involve topical administration of an effector component that targets intracellular biological targets to such organs, in combination with a saponin component that enhances the effective uptake of the effector component into cells and / or enhances the effective delivery of the effector component within cells where the biological target is present. For example, the effector component may be an oligonucleotide therapeutic that targets gene products associated with CNS and / or ocular disorders. Due to the cellular uptake stimulating and / or endosomal escape enhancing effects of the saponin component, the neuropharmaceuticals and ophthalmic compositions presented herein for topical administration to the CNS and / or eye, respectively, can be formulated with lower concentrations of the effector component and / or lower volumes, which provides safety benefits to neurons and patient comfort.

This invention relates to the field of biomedicine and discloses a composition for treating non-small cell lung cancer metastasis that targets replication stress vulnerability and its application. The composition includes a dual-responsive polymer prodrug, which consists of a block copolymer backbone, a matrix metalloproteinase cleavage peptide sequence coupled to the hydrophilic end, and an active molecular group coupled to the hydrophobic end based on an asymmetric grafting structure. The active molecular group comprises a replication stress inducer and an ATR kinase inhibitor. This invention maintains the amorphous phase of the micelle core through the asymmetric grafting structure, eliminating the permeation barrier caused by spontaneous crystallization of components. This amorphous core provides a proton permeation channel, ensuring the synchronous in-situ release of multiple target drugs, thereby blocking the DNA replication fork repair pathway and inducing mitotic catastrophe, maintaining the spatiotemporal overlap of multiple drug interventions in the pathological target area, and avoiding the risk of drug resistance.

This invention discloses a method for rice to withstand heat stress. RMI1 Genes and their applications. Among them... RMI1 The nucleotide sequence of the gene is shown in SEQ ID No. 1, and the amino acid sequence of the protein it encodes is shown in SEQ ID No. 2; this invention verifies RMI1 The function of the gene, RMI1 protein is located in the cell nucleus, rmi1-1 In mutants RMI1 The deletion of 33 base pairs in the gene results in the loss of 11 amino acids in the RMI1-1 protein, making... rmi1-1 High temperatures during the seedling stage cause a large number of abnormal chromosomes to adhere and fragment during the late mitotic phase of root tip cells, resulting in stunted plant growth and development. rmi1-1 High temperatures during the reproductive growth period of plants lead to a large number of chromosome fragments and adhesions in the late stage of meiosis I, resulting in sterility; high temperatures also affect the interaction between RMI1-1 protein and topoisomerase TOP3α and helicase RECQ4. rmi1-cr3 Frameshift mutations lead to abnormal embryo and endosperm development; overexpression RMI1 This invention can enhance the heat resistance of rice. RMI1 The analysis of gene function provides genetic resources for the breeding of heat-resistant rice varieties.

The present disclosure provides methods for inducing cell cycle reentry of postmitotic cell. The present disclosure further provides cells and compositions for treating diseases, such as cardiovascular diseases, neural disorders, hearing loss, and diabetes.

The invention relates to a method of preparing a suspension of mitotically suppressed cells, comprising the steps of a) providing cells suspended in a cell culture medium, and b) suppressing the mitotic activity of the cells in the suspension, thereby obtaining mitotically suppressed cells. The step of suppressing the mitotic activity of the cells comprises the step of hypotonic treating the suspension, followed by exposing the cells to at least one freeze-thaw cycle, or vice versa or exposing the cells to two or more freeze-thaw cycles, optionally preceded by a hypotonic treatment of the suspension. In the method of the present invention the hypotonic treatment of the suspension comprises the step of adding liquid, such as water, to the suspension comprising the cells to form a hypotonic cell culture medium. The invention further relates to a method for culturing cells of interest and to the use of a hypotonic cell culture medium.

The present application relates to the field of aquatic organism breeding technology, and particularly relates to a method for preparing rainbow trout tetraploid fry. The method provided by the present application comprises the following steps: obtaining fertilized eggs by dry fertilization of naturally matured rainbow trout parents, inducing the rainbow trout fertilized eggs to obtain tetraploid rainbow trout after 6.2-6.4 hours, and the duration of the induction is 10-18 minutes; after the tetraploid rainbow trout fry is obtained by induction, the chromosome ploidy of the fish is determined by using techniques such as chromosome karyotype analysis and flow cytometry DNA content determination, and the tetraploid rainbow trout fry is identified and screened for cultivation. The present application adopts a drug induction method, and controls the starting time and duration of the induction to inhibit the first mitosis time of the fertilized eggs, thereby improving the induction rate and survival rate of the tetraploid rainbow trout, and the induction rate of the tetraploid rainbow trout can reach 25-30%, and the survival rate of the fry can reach more than 90%.

The present application relates to the technical field of pharmacy, more particularly to a small molecule inhibitor, a synthetic method and an application. The small molecule inhibitor is a chemical structural formula as shown in formula (I) or a pharmaceutically acceptable salt comprising the chemical structural formula as shown in formula (I); the small molecule inhibitor has biological activity and can effectively inhibit cell mitosis, which is of great significance for preventing abnormal cell proliferation and the occurrence of cancer.

Provided is a method for culturing a sample of cells, which includes circulating epithelial cells, peripheral blood mononuclear cells (PBMC), or body fluid-derived cell samples (e.g. blood, ascites, pleural effusions, cerebrospinal fluids, perfusion fluids, sputum, and urine), or liquid biopsy-derived cell samples in presence of Bone Morphogentic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist, when culturing the circulating epithelial cells and relevant blood cells. Also provided is use of cell medium having a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist in obtaining a cell culture of circulating epithelial cells, PBMC and body fluid-derived cells.

Provided is a method for culturing a sample of cells, which includes circulating epithelial cells, peripheral blood mononuclear cells (PBMC), or body fluid-derived cell samples (e.g. blood, ascites, pleural effusions, cerebrospinal fluids, perfusion fluids, sputum, and urine), or liquid biopsyderived cell samples in presence of Bone Morphogentic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist, when culturing the circulating epithelial cells and relevant blood cells. Also provided is use of cell medium having a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist in obtaining a cell culture of circulating epithelial cells, PBMC and body fluid-derived cells.